Stephanie Kvas, DPM
Foot & Ankle Surgery · New Prague, MNNPI 1861855637
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (49.4%), education and food and beverage — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Arthrex at 45.7% of the total. Reporting peaked in 2022 at $3,360 and has fallen 98.7% since, to $45 in 2025.
Across 38 payments — averaging $116.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$2K
- Gemini Medical LLC$1K
- Treace Medical Concepts, Inc.$677
- Stryker$267
- Integra Lifesciences Corporation$90
- Organogenesis Inc.$38
- plus $57 from 2 others
What the payments were for
- Travel & lodging$2,18649%
- Food & beverage$1,04224%
- Education$1,20027%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 13 | $2,025 |
| Gemini Medical LLC | 7 | $1,274 |
| Treace Medical Concepts, Inc. | 4 | $677 |
| Stryker | 7 | $267 |
| Integra Lifesciences Corporation | 2 | $90 |
| Organogenesis Inc. | 2 | $38 |
| Foundation Medical, LLC | 2 | $33 |
| Smith+Nephew | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,428 in reported general payments places this provider in the 60th percentile of 102 foot & ankle surgery providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin-Polymyxin-HydrocortNeomycin/Polymyxin B/Hydrocort | 18 | $999 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in New Prague
- Johannes CoetzeeEdina$4.7M
- Troy BoffeliSaint Paul$1.7M
- Jeffrey SeyboldEdina$270K
- Kyle AbbenSt Louis Park$130K
- Collin MesserlySaint Paul$50K
- Ryan ReinkingDuluth$48K
- Kevin MahoneyMarshall$39K
- Bethany StaehnkeCrookston$27K
- Amber WibbelsRoseau$24K
- Ruixian YueWoodbury$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.